NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Go back to NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
(NASDAQ: NTHI) Delayed: 2.90 +0.13 (4.69%)
Previous Close $2.77    52 Week High $ 
Open $2.80    52 Week Low $ 
Day High $2.96    P/E N/A 
Day Low $2.75    EPS $ 
Volume 106,237